Boron Chemistry for Medical Applications

Химия бора для медицинских применений
Narayan S. Hosmane, Yinghuai Zhu, Fayaz Ali
2020-02-13

boron neutron capture therapy (BNCT)boron-containing compoundscarboranesmedicinal chemistrytumor-targeted delivery
Boron compounds now have many applications in a number of fields, including Medicinal Chemistry. Although the uses of boron compounds in pharmacological science have been recognized several decades ago, surprisingly few are found in pharmaceutical drugs. The boron-containing compounds epitomize a new class for medicinal chemists to use in their drug designs. Carboranes are a class of organometallic compounds containing carbon (C), boron (B), and hydrogen (H) and are the most widely studied boron compounds in medicinal chemistry. Additionally, other boron-based compounds are of great interest, such as dodecaborate anions, metallacarboranes and metallaboranes. The boron neutron capture therapy (BNCT) has been utilized for cancer treatment from last decade, where chemotherapy and radiation have their own shortcomings. However, the improvement in the already existing (BPA and/or BSH) localized delivery agents or new tumor-targeted compounds are required before realizing the full clinical potential of BNCT. The work outlined in this short review addresses the advancements in boron containing compounds. Here, we have focused on the possible clinical implications of the new and improved boron-based biologically active compounds for BNCT that are reported to have in vivo and/or in vitro efficacy.
1
Boron compounds represent an underused but promising class of structures for medicinal chemistry and pharmaceutical drug design.
2
Boron neutron capture therapy offers a cancer-treatment approach that may address limitations associated with conventional chemotherapy and radiation.
3
Carboranes are the most extensively studied boron-containing compounds, alongside dodecaborate anions, metallacarboranes, and metallaboranes.
4
Recent boron-based biologically active compounds have demonstrated in vitro and/or in vivo efficacy, supporting their possible clinical relevance for BNCT.
5
The clinical potential of BNCT remains constrained by the need for improved localized delivery agents beyond BPA and BSH, or new tumor-targeted boron compounds.

boron-containing biologically active compounds for boron neutron capture therapy (BNCT), including carboranes, dodecaborate anions, metallacarboranes, and metallaboranes

their clinical potential for cancer treatment, particularly in vivo/in vitro efficacy and tumor-targeted delivery

Publication Details
Publication Date
2020-02-13
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Narayan S. Hosmane
Yinghuai Zhu
Fayaz Ali
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%